Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets

Pharm Biol. 2023 Dec;61(1):1186-1210. doi: 10.1080/13880209.2023.2241518.

Abstract

Context: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still ongoing and currently the most striking epidemic disease. With the rapid global spread of SARS-CoV-2 variants, new antivirals are urgently needed to avert a more serious crisis. Inhibitors from traditional medicines or natural plants have shown promising results to fight COVID-19 with different mechanisms of action.

Objectives: To provide comprehensive and promising approaches to the medical community in the fight against this epidemic by reviewing potential plant-derived anti-SARS-CoV-2 inhibitors.

Methods: Structural databases such as TCMSP (http://lsp.nwu.edu.cn/tcmsp.php), TCM Database @ Taiwan (http://tcm.cmu.edu.tw/), BATMAN-TCM (http://bionet.ncpsb.org/batman-tcm/) and TCMID (http://www.megabionet.org/tcmid/), as well as PubMed, Sci Finder, Research Gate, Science Direct, CNKI, Web of Science and Google Scholar were searched for relevant articles on TCMs and natural products against SARS-CoV-2.

Results: Seven traditional Chinese medicines formulas have unique advantages in regulating the immune system for treating COVID-19. The plant-derived natural compounds as anti-SARS-CoV-2 inhibitors were identified based on 5 SARS-CoV-2 key proteins, namely, angiotensin-converting enzyme 2 (ACE2), 3 C-like protease (3CLpro), papain-like protease (PLpro), spike (S) protein, and nucleocapsid (N) protein.

Conclusions: A variety of natural products, such as flavonoids, terpenoids, phenols, and alkaloids, were identified, which could be used as potential SASR-Cov-2 inhibitors. These shed new light on the efficient discovery of SASR-Cov-2 inhibitors from natural products.

Keywords: COVID-19; SARS-CoV-2; anti-SARS-CoV-2 strategies; natural products; phytochemicals; traditional chinese medicines.

Publication types

  • Review

MeSH terms

  • Biological Products* / pharmacology
  • Biological Products* / therapeutic use
  • COVID-19*
  • Humans
  • Peptide Hydrolases
  • SARS-CoV-2

Substances

  • Peptide Hydrolases
  • Biological Products

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (NO. 81873071), Natural Science Foundation of Guangdong Province (NO. 2021A1515011512), Supporting talent development plan of Guangdong Pharmaceutical University and Project funding of Yangtze River Pharmaceutical Group Jiangsu Pharmaceutical Co., Ltd.